title: Current clinical application of serum biomarkers to detect ovarian cancer.
abstract: For the last decades, hundreds of potential serum biomarkers have been assessed in diagnosing of ovarian cancer including the wide spectrum of cytokines, growth factors, adhesion molecules, proteases, hormones, coagulation factors, acute phase reactants, and apoptosis factors but except CA125 none of them have been applied to everyday clinical practice. Nowadays, the growing number of evidence suggests that the classic marker CA125 should be accompanied by HE4 and in fact, Risk of Ovarian Malignancy Algorithm (ROMA) is becoming more and more widespread in clinical practice for the evaluation of adnexal masses. Early ovarian cancer is often asymptomatic, so the challenge still exists to develop serum markers suitable for early diagnosis and screening. Current knowledge strongly points to different mechanisms of pathogenesis, genetic disturbances and clinical course of major histological subtypes of ovarian cancer. Thus, future biomarker/multimarker panels should take into consideration the implications of different molecular patterns and biological behavior of various subtypes of ovarian cancer. Very promising are studies on miRNAs - small non-protein coding gene-regulatory RNA molecules functionally involved in the pathogenesis of cancers acting as oncogenes (oncomirs) or tumor suppressors. The studies devoted to ovarian cancer tissue miRNA profiling have shown that miRNAs could be useful in diagnosing and predicting the OC outcome. They also confirmed that OC is a highly heterogeneous disease, gathering four distinct histological tumor subtypes characterized not only by distinct origin, behavior and response to chemotherapy but also by different patterns of miRNA expression.
authors: Department of Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
authors: Marek
authors: M
authors: Nowak
authors: Department of Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
authors: Łukasz
authors: Ł
authors: Janas
authors: Department of Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
authors: Grzegorz
authors: G
authors: Stachowiak
authors: Department of Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
authors: Tomasz
authors: T
authors: Stetkiewicz
authors: Department of Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
authors: Jacek R
authors: JR
authors: Wilczyński
keywords: CA125; HE4; OVA1; ROMA; miRNAs; ovarian cancer; tumor markers